Novo Nordisk spotlights star diabetes drugs in massive TV ad campaigns

In 2021, pharmaceutical firm Novo Nordisk spent enormous sums of money on advertising diabetes drugs Ozempic and Rybelsus. (Corrected)

by benjamin werner Christensen, translated by daniel pedersen

(Corrected at 9:25 am, January 25: An earlier version of the article did not contain sales figures in the correct currency for Rybelsus and Ozempic.)

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Eli Lilly considers copying Novo Nordisk's semaglutide branding strategy
For subscribers
Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook
For subscribers
Catalent behind Novo Nordisk's supply issues, says media
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers

Pharma & biotech

Vaccine breakthrough behind mRNA shots wins Nobel Prize

For subscribers

WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers
Country Manager: Indians will have to wait for Wegovy until 2026
Up to 40% of the female population aged 30-49 in India is overweight.
For subscribers
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech